Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade

Pancreatic ductal adenocarcinoma (PDAC) patients have a 5-year survival rate of only 8% largely due to late diagnosis and insufficient therapeutic options. Neutrophils are among the most abundant immune cell type within the PDAC tumor microenvironment (TME), and are associated with a poor clinical p...

Full description

Saved in:
Bibliographic Details
Published in:Nature communications Vol. 12; no. 1; pp. 3414 - 15
Main Authors: Nielsen, Sebastian R., Strøbech, Jan E., Horton, Edward R., Jackstadt, Rene, Laitala, Anu, Bravo, Marina C., Maltese, Giorgia, Jensen, Adina R. D., Reuten, Raphael, Rafaeva, Maria, Karim, Saadia A., Hwang, Chang-Il, Arnes, Luis, Tuveson, David A., Sansom, Owen J., Morton, Jennifer P., Erler, Janine T.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 07.06.2021
Nature Publishing Group
Nature Portfolio
Subjects:
ISSN:2041-1723, 2041-1723
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first